Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS for 200 ordinary shares to one ADS for 2,000 ordinary shares. Trading reflecting the new ratio is expected to begin on or about March 2, 2026.
For ADS holders, this acts as a one-for-ten reverse ADS split: every 10 existing ADSs will be exchanged for 1 new ADS, with no action needed for uncertificated holders. Fractional ADSs will be sold by the depositary, and net cash from those fractions will be distributed to holders.
The move is primarily intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The ADSs will keep the “PPBT” symbol and receive a new CUSIP. The ratio change does not affect the company’s ordinary shares on the Tel Aviv Stock Exchange.
Susquehanna Securities, LLC filed a Schedule 13G reporting beneficial ownership of 93,953,400 Ordinary Shares of Purple Biotech Ltd., equal to 5.2% of the class. The position is held through 469,767 ADSs, with each ADS representing 200 Ordinary Shares.
Based on the company’s disclosure that 1,806,089,801 Ordinary Shares were outstanding as of October 20, 2025, Susquehanna’s holdings represent a significant but minority passive stake. The filing states the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Purple Biotech.
Purple Biotech Ltd. submitted a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate Presentation January 2026.” This presentation is included as Exhibit 99.1 and is intended to provide current information about the company in January 2026.
The report is formally authorized on behalf of Purple Biotech Ltd. and is signed by Chief Executive Officer Gil Efron, dated January 12, 2026.
Purple Biotech Ltd. reported a key preclinical milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform, in a non-human primate toxicology study. IM1240’s proprietary CD3 capping design enabled dosing up to 300-fold higher than a non-capped comparator, with markedly reduced immune-related toxicity and minimal cytokine release, suggesting a wider safety margin than certain current T cell engagers. The study also showed a favorable pharmacokinetic profile, with increased systemic exposure and a prolonged circulating half-life linked to its human serum albumin moiety and capping design. Purple Biotech plans to advance IM1240 toward first-in-human clinical trials, with a regulatory submission targeted for the second half of 2026, while continuing to develop its broader oncology pipeline, including CAPTN-3 candidates IM1240 and IM1305, and clinical-stage assets CM24 and NT219.
Purple Biotech Ltd. reports that shareholders approved all proposals presented at its Extraordinary General Meeting held on December 15, 2025 at the company offices in Rehovot, Israel. The proposals were described in the company proxy statement furnished on October 28, 2025 and received the requisite votes under Israeli Companies Law and the company articles of association.
The company also states that this Form 6-K, including its exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, so those offering documents now include these meeting results.
Purple Biotech Ltd. filed a Form 6-K to notify investors that it has released an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025.” The presentation is furnished as Exhibit 99.1. This type of filing is mainly informational, giving the market updated background on the company and its activities rather than announcing a specific transaction or new financial results.
Purple Biotech Ltd. furnished a Form 6-K announcing that, on November 14, 2025, it issued a press release titled “Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update,” attached as Exhibit 99.1.
The Form 6-K, including all exhibits, is incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements, making it part of those filings from the date of submission, to the extent not superseded by later reports.
Purple Biotech Ltd. furnished a Form 6-K noting it issued a press release titled “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform.” The press release is included as Exhibit 99.1 and is dated October 29, 2025.
The filing is administrative and points readers to the attached press release for details on the IM1240 manufacturing milestone from the CAPTN-3 platform.
Purple Biotech Ltd. (PPBT) announced an Extraordinary General Meeting of Shareholders to be held on December 15, 2025 at 4:30 p.m. Israel time at its executive offices, 4 Oppenheimer Street, Science Park, Rehovot, Israel.
The company furnished a Notice and Proxy Statement (with a Voting Slip for ordinary shareholders) as Exhibit 99.1. BNY Mellon, the ADS depositary, will distribute a Voting Instruction Form to ADS holders (attached as Exhibit 99.2). The materials are incorporated by reference into existing Form S-8 and Form F-3 registration statements.
Purple Biotech Ltd. (PPBT) furnished a Form 6-K reporting that on October 20, 2025 it issued a press release titled “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification.”
The press release is included as Exhibit 99.1. This filing serves as a notice to investors about the company’s receipt of a Nasdaq minimum bid price notification and provides the related disclosure via the attached exhibit.